Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Checking in on the Migraine landscape and impact oral and IV CGRPs might have on prescribing.

Ticker(s): BHVN, AMGN, LLY, TEVA

Who's the expert?

Name: Dr Stewart Tepper - MD

Institution: Dartmouth-Hitchcock Medical Center

  • Clinical Neurologist. Director of the Dartmouth Headache Center, and Professor of Neurology at Geisel School of Medicine, Dartmouth.
  • Treats~150 migraine patients per month.
  • Previously investigator in the rimegepant Phase 2 trial when it was owned by BMS. and has published over 330 peer-reviewed manuscripts, editorials, and books.

Interview Questions
Q1.

Questions to come, or add your own! 

Added By: joe_mccann
Q2.

1. Has the reimbursement landscape for the class been improving?

2. Do you have a preference for any of the agents I.e. aimovig over Ajovy?

3. Has there been trouble getting CGRPs for patients already on Botox? Do you try patients on both? For new patients do you try Botox first or prefer CGRPs?

Added By: userad9707da
Q3.

1. In your opinion is there a real concern for liver toxicity for ubrogepant over rimegepant?

2. Given the Zydis formulation of rimegepant has a quicker onset of action would you prefer this over Ubrogepant.

Added By: userad9707da

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.